Finding New Markers of Lung Disease Caused by Mycobacterium Abscessus in Cystic Fibrosis
Studies immune response markers in adults with cystic fibrosis and Mycobacterium abscessus lung infection.
Key facts
- Who runs it
- Ospedale San Raffaele
- Where
- Milan, ItalySee the site
- Trial code
- Registry title
- Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 8 Apr 2021
- Expected to end
- 30 Mar 2027
- Type of study
- Observational, 4 groups
- Treatments tested
- Luminex; scRNAsec
- Record updated
- 16 May 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a certain diagnosis of cystic fibrosis who are seen in normal clinical care. It studies markers of Mycobacterium abscessus lung disease.
- Age
- Older than 18 years
- Sex
- Both sexes can join
- Disease stage
- Certain diagnosis of cystic fibrosis. The record does not name a disease stage.
Main reasons for not taking part
- Cannot understand the instructions and information given
- Cannot adequately accept the study methods
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients with a certain diagnosis of cystic fibrosis and visited during normal clinical practice, in accordance with the standard operating procedures in force at the Centres
- Both sexes
- Age >18 years
- Obtaining informed consent for patients (based on the procedures established by the protocol)
Who cannot take part
- Patients unable to understand the instructions and information provided and be able to adequately accept the study methods
Where in Italy
- Ospedale San RaffaeleMilan, ItalyContact: Nicola I Lorè, PhDTaking people
About the trial
What the trial wants to find out
In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M. abscessus lung disease in patients suffering from cystic fibrosis with the aim of increasing current knowledge available on the development and progression of lung disease.
The 4 groups in the trial
- CF patients with chronic M. abscessus infection
Treatment: Luminex; scRNAsec
- CF patients with M. abscessus pulmonary disease
Treatment: Luminex; scRNAsec
- CF patients with no history of M. abscessus infection
Treatment: Luminex; scRNAsec
- Healty Controls
Treatment: Luminex; scRNAsec
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis
- Plain-language title
- Finding New Markers of Lung Disease Caused by Mycobacterium Abscessus in Cystic FibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 May 2024